Merck's GARDASIL, The First Vaccine For HPV, Gains Approval In China

Merck, known as MSD outside the U.S. and Canada, has announced that GARDASIL® is approved by China’s National Medical Products Administration (NMPA). GARDASIL® is a vaccine for treating Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) for males 9-26 years of age to help prevent certain HPV-related cancers and diseases. 

This milestone marks GARDASIL as the first HPV vaccine available for males in China. The vaccine is approved to help prevent anal cancers caused by HPV Types 16 and 18, genital warts caused by Types 6 and 11, and precancerous anal lesions (grades 1, 2, and 3) linked to HPV Types 6, 11, 16, and 18. 

Joseph Romanelli, president of Human Health International, Merck, commented, “The approval of GARDASIL for use in males 9-26 in China is a significant step forward in advancing public health. Since first approval, our HPV vaccines have helped protect over 50 million females in China from certain HPV-related cancers and diseases. With this expanded approval, we look forward to helping protect this new population of Chinese males from certain HPV-related cancers and diseases.”